H.C. Wainwright raised the firm’s price target on Tyra Biosciences (TYRA) to $32 from $30 and keeps a Buy rating on the shares. The firm says TYRA-300 initial clinical data “look impressive.” It increased the probability of approval in metastatic urothelial carcinoma to 45% from 35%.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on TYRA:
- Judge blocks Tapestry-Capri deal, Centene reports Q3 beat: Morning Buzz
- Tyra Bioscience Shows Promise with TYRA-300 Results
- Tyra Biosciences’ TYRA-300 shows anti-tumor activity in proof-of-concept trial
- Tyra Biosciences upgraded to Buy from Neutral at BofA
- Tyra Biosciences price target raised to $30 from $25 at H.C. Wainwright